PS1219 CAUSES OF NON – ELIGIBILITY FOR CD19 CAR T-CELL IMMUNOTHERAPY IN PATIENTS WITH RELAPSE/REFRACTORY DLBCL. EXPERIENCE OF SAINT-LOUIS HOSPITAL

Authors :: M. Berquier
N. Parquet
Isabelle Madelaine-Chambrin
Elie Azoulay
Catherine Thieblemont
Sophie Bernard
Michael Darmon
Jérôme Paillassa
Laetitia Vercellino
A. Brignier
Jérôme Larghero
D. Rea
R. Di Blasi
Véronique Meignin
E. De Kerviler
Source :: HemaSphere. 3:556
Publication Year :: 2019
Publisher :: Ovid Technologies (Wolters Kluwer Health), 2019.

Subjects :: Oncology
medicine.medical_specialty
biology
business.industry
medicine.medical_treatment
Hematology
Immunotherapy
CD19
Refractory
Internal medicine
medicine
biology.protein
In patient
Car t cells
business

Tools